Brief: Inventiva Provides An Update On Its NATiV3 Clinical Program Evaluating Lanifibranor In Patients With MASH/NASH And Its Financial Position
05/07/2024 21:03
July 5 (Reuters) - Inventiva SA IVAA.PA :
* INVENTIVA PROVIDES AN UPDATE ON ITS NATIV3 CLINICAL
PROGRAM
EVALUATING LANIFIBRANOR IN PATIENTS WITH MASH/NASH AND ITS
FINANCIAL POSITION
Source text for Eikon: ID:nGNX3DYHcN
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030